AI drug discovery startup Basecamp Research raises $140M
$140M. Basecamp Research just landed a Series C that puts AI drug discovery on the venture map—Bill Maris's S32 leading, Nvidia and NATO co-investing.
Why it matters
A major capital injection into AI-driven drug discovery signals institutional confidence in the model's ability to compress R&D timelines and cost. For practitioners building AI in life sciences, this validates the category and raises the bar for what investors expect from biotech AI plays.
The key facts
9 to knowSeries C: $140M
Led by S32 (Bill Maris fund)
Co-investors: Nvidia, NATO, Anthology Fund, and 10+ others
Company: Basecamp Research Ltd.
Category: AI drug discovery
Lead: S32 (Bill Maris fund affiliated with Google)
Investors: NATO, Nvidia, Anthology Fund, and 'more than a dozen' others
Company: Basecamp Research Ltd., AI drug discovery
Date: September 23, 2026
Go to the source
SiliconAnglesiliconangle.com
Publisher excerpt: Basecamp Research Ltd. today announced that it has raised $140 million in funding from a group of prominent investors. S32, a fund affiliated with Google LLC co-founder Bill Maris, led the Series C round. It was joined by more than a dozen other investors. The group included NATO, Nvidia Corp. and…